Across TCGA pan-cancer cohorts, POLR3C mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated POLR3C data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher POLR3C mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated POLR3C expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, LUAD, and CCRCC are the cancer types where POLR3C mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	II,III,IV	0.578	0.868	<.001	60	view →
LUAD	OS	Median	All	1.000	0.764	.004	28	view →
CCRCC	DFS	Tertile	III,IV	0.309	0.714	<.001	24	view →
LSCC	DFS	Median	II,III,IV	0.846	0.547	.003	23	view →
GBM	DFS	Median	All	0.418	0.240	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: POLR3C tumor-vs-normal RNA expression · all POLR3C data types